摘要
由于传统的以他莫昔芬(tamoxifen,TAM)和芳香化酶抑制剂(arimedex)为主的内分泌治疗中存在耐药性,最近出现了将热休克蛋白90(heatshockprotein90,HSP90)作为乳腺癌治疗新靶点的独特思路和手段。作为热休克蛋白家族的一员,HSP90影响在乳腺癌疾病进程和耐药机制中起重要作用的蛋白的稳定性和功能,在经典的乳腺癌雌激素信号途径中起独特作用,影响雌激素受体(estrogenreceptor,ER)的量和结合激素的能力。本文综述了将HSP90作为乳腺癌治疗靶点的理论基础和实践。
Because there is drug resistance in traditional endocrine therapy based on tamoxifen and arimedex,a distinctive presumption and method of making HSP90 acting as a new kind of therapeutic target appeared recently. As a member of heat shock protein family, HSP90 impacts on the stability and function of proteins which are very important in the pathology and mechanism of drug resistance of breast cancer, it has distinctive function in the classical estrogen receptor signal pathway in breast neoplasms, because it has influence on the quantity and ability of binding estrogen of ER. The review focused on the rationale and practice of HSP90 acting as therapeutic target.
出处
《现代肿瘤医学》
CAS
2007年第2期270-273,共4页
Journal of Modern Oncology
基金
国家自然科学基金赞助项目(编号30171064)
关键词
热休克蛋白90
分子伴侣
雌激素受体
靶向治疗
乳腺癌
内分泌治疗
耐药
HSP90
molecule chaperon
estrogen receptor
targeted therapy
breast neoplasms
endocrine therapy
drug resistance
